Tablet

Empagliflozin 10mg

Empagliflozin

SGLT-2 inhibitor that reduces cardiovascular death by 38% and heart failure hospitalization by 35% in T2DM patients with established cardiovascular disease (EMPA-REG OUTCOME trial), the first antidiabetic drug to demonstrate such landmark mortality benefit. Approved for heart failure regardless of diabetes status, establishing a new paradigm in cardiometabolic medicine.

Strengths

10mg / 25mg

Packing

10 tablets/strip

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request Quotation WhatsApp

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition

Empagliflozin 10mg / 25mg

Dosage Form

Tablet

Available Strengths

10mg / 25mg

Packing

10 tablets/strip

Route of Administration

Oral, with or without food (morning)

Dosage

10mg once daily in the morning; may increase to 25mg once daily; also approved 10mg for heart failure regardless of diabetes

Indications

Type 2 diabetes mellitus (glycemic control), cardiovascular death risk reduction in T2DM with established CVD, heart failure with reduced ejection fraction

Country of Origin

India (WHO-GMP Certified)

Storage

Store at 25°C, protected from moisture

Shelf Life

36 months

Side Effects

Urinary tract infections, genital mycotic infections, polyuria, volume depletion, ketoacidosis (rare), Fournier's gangrene (rare)

Precautions

Not for type 1 diabetes; withhold before major surgery; monitor renal function (not recommended if eGFR <45); DKA risk including euglycemic DKA; risk of lower limb amputations (class effect)

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Tablet

Glimepiride 2mg

Glimepiride

Third-generation sulfonylurea that stimulates pancreatic beta-cell insulin secretion via selective SUR1 receptor binding, offering a lower hypoglycemia risk compared to earlier sulfonylureas due to glucose-dependent activity. The most cost-effective oral antidiabetic agent in its class and a cornerstone of type 2 diabetes management in emerging markets.

1mg / 2mg / 3mg / 4mg

Tablet

Sitagliptin 100mg

Sitagliptin Phosphate

First-in-class DPP-4 inhibitor that amplifies incretin-mediated glucose-dependent insulin secretion while suppressing glucagon, offering glycemic control without weight gain or intrinsic hypoglycemia risk. Once-daily dosing, renal dose adjustment flexibility, and a decade-long cardiovascular safety record make it a globally preferred add-on antidiabetic.

25mg / 50mg / 100mg

Tablet

Vildagliptin 50mg

Vildagliptin

Selective DPP-4 inhibitor with potent enzyme inhibition that improves glycemic control through enhanced incretin-mediated insulin secretion and suppressed post-meal glucagon release. Widely prescribed as a fixed-dose combination with metformin (Galvusmet) offering convenient dual-mechanism therapy without weight gain.

50mg

Need bulk pricing for Empagliflozin 10mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote